Ridaforolimus

Ridaforolimus

File:Deforolimus.svg
Clinical data
ATC code	L01XE19 (WHO)
Identifiers
IUPAC name (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate
CAS Number	572924-54-0 N
PubChem CID	11520894
ChemSpider	24597928 Y
UNII	48Z35KB15K
ChEBI	CHEBI:82677 N
ChEMBL	ChEMBL2103804 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C53H84NO14P
Molar mass	990.22 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1CCC2CC(/C(=C/C=C/C=C/C(CC(C(=O)C(C(/C(=C/C(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC
InChI InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1 Y Key:BUROJSBIWGDYCN-GAUTUEMISA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Ridaforolimus
Articles
Most recent articles on Ridaforolimus Most cited articles on Ridaforolimus Review articles on Ridaforolimus Articles on Ridaforolimus in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ridaforolimus Images of Ridaforolimus Photos of Ridaforolimus Podcasts & MP3s on Ridaforolimus Videos on Ridaforolimus
Evidence Based Medicine
Cochrane Collaboration on Ridaforolimus Bandolier on Ridaforolimus TRIP on Ridaforolimus
Clinical Trials
Ongoing Trials on Ridaforolimus at Clinical Trials.gov Trial results on Ridaforolimus Clinical Trials on Ridaforolimus at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ridaforolimus NICE Guidance on Ridaforolimus NHS PRODIGY Guidance FDA on Ridaforolimus CDC on Ridaforolimus
Books
Books on Ridaforolimus
News
Ridaforolimus in the news Be alerted to news on Ridaforolimus News trends on Ridaforolimus
Commentary
Blogs on Ridaforolimus
Definitions
Definitions of Ridaforolimus
Patient Resources / Community
Patient resources on Ridaforolimus Discussion groups on Ridaforolimus Patient Handouts on Ridaforolimus Directions to Hospitals Treating Ridaforolimus Risk calculators and risk factors for Ridaforolimus
Healthcare Provider Resources
Symptoms of Ridaforolimus Causes & Risk Factors for Ridaforolimus Diagnostic studies for Ridaforolimus Treatment of Ridaforolimus
Continuing Medical Education (CME)
CME Programs on Ridaforolimus
International
Ridaforolimus en Espanol Ridaforolimus en Francais
Business
Ridaforolimus in the Marketplace Patents on Ridaforolimus
Experimental / Informatics
List of terms related to Ridaforolimus

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ridaforolimus (also known as AP23573 and MK-8669; formerly known as Deforolimus) is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma.

Commercial arrangements

Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. On May 5, 2010, Ariad Pharmaceuticals and Merck & Company announced a clinical development and marketing agreement. With this agreement, Ariad received $125 million in upfront payments from Merck and $53 million in milestone payments. Future payments are triggered upon acceptance of the NDA by the FDA with another payment when the drug receives marketing approval. There are similar milestones for acceptance and approval in both Europe and Japan. Other milestone payments are tied to revenue goals for the drug. ARIAD has opted to co-promote ridaforolimus in the U.S. Merck plans to submit a New Drug Application (NDA) for ridaforolimus to the U.S. Food and Drug Administration (FDA) and a marketing application in the European Union in 2011. After formal rejection by the FDA in June 2012 ARIAD/MSD decided to withdraw their EMA application for Ridaforolimus in November 2012.

Clinical trials

Phase III SUCCEED

On June 6, 2011, Ariad and Merck announced detailed results from the largest randomized study ever in the soft tissue and bone sarcoma population, the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. In this patient population, ridaforolimus improved progression-free survival (PFS) compared to placebo, the primary endpoint of the study. The complete study results were presented by Sant P. Chawla, M.D., director, Sarcoma Oncology Center, Santa Monica, CA, during the 2011 American Society of Clinical Oncology (ASCO) annual meeting.
The SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus) trial was a randomized (1:1), placebo-controlled, double-blind study of oral ridaforolimus administered at 40 mg/day (five of seven days per week) in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. Oral ridaforolimus was granted a Special Protocol Assessment (SPA) by the FDA for the SUCCEED trial.
Based on 552 progression-free survival (PFS) events in 711 patients, (ridaforolimus (N=347), placebo (N=364) determined by an independent radiological review committee, the study achieved its primary endpoint of improvement in PFS, with a statistically significant (p=0.0001) 28 percent reduction in the risk of progression or death observed in those treated with ridaforolimus compared to placebo (hazard ratio=0.72). Median PFS was 17.7 weeks for those treated with ridaforolimus compared to 14.6 weeks in the placebo group. Furthermore, based on the full analysis of PFS determined by investigator assessment, there was a statistically significant (p<0.0001) 31 percent reduction by ridaforolimus in the risk of progression or death compared to placebo (hazard ratio=0.69). In the investigator assessment analysis, median PFS was 22.4 weeks for those treated with ridaforolimus compared to 14.7 weeks in the placebo group

External links

• ARIAD Pharmaceuticals